Charles Swanton
Overview
Explore the profile of Charles Swanton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
379
Citations
42381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Middleton G, Robbins H, Fletcher P, Savage J, Mehmi M, Summers Y, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):67.
PMID: 40069402
There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with...
3.
Leung M, Swanton C, McGranahan N
Nat Rev Genet
. 2025 Mar;
PMID: 40065153
Deciphering metastatic processes is crucial for understanding cancer progression and potential treatment options. Genetic studies of model systems engineered to mimic metastatic disease, including organoids, genetically engineered mice and human...
4.
Dowgier G, Hobbs A, Greenwood D, Shawe-Taylor M, Stevenson-Leggett P, Bazire J, et al.
Vaccine
. 2025 Mar;
54:126960.
PMID: 40056806
Emerging SARS-CoV-2 variants require rapid assessments of pathogenicity and evasion of existing immunity to inform policy. A crucial component of these assessments is accurate estimation of serum neutralising antibody titres...
5.
Al Bakir M, Reading J, Gamble S, Rosenthal R, Uddin I, Rowan A, et al.
Nature
. 2025 Feb;
PMID: 39972134
Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (EGFR)-driven lung cancers. We tracked the phylogenetic history of an EGFR mutant lung cancer treated with erlotinib,...
6.
Bentham R, Jones T, Black J, Martinez-Ruiz C, Dietzen M, Litovchenko M, et al.
Nat Genet
. 2025 Feb;
57(3):694-705.
PMID: 39966644
Recognition and elimination of pathogens and cancer cells depend on the adaptive immune system. Thus, accurate quantification of immune subsets is vital for precision medicine. We present immune lymphocyte estimation...
7.
Swanton C, Bachtiar V, Mathews C, Brentnall A, Lowenhoff I, Waller J, et al.
Clin Trials
. 2025 Jan;
17407745241302477.
PMID: 39862108
Background/aims: Certain sociodemographic groups are routinely underrepresented in clinical trials, limiting generalisability. Here, we describe the extent to which enriched enrolment approaches yielded a diverse trial population enriched for older...
8.
Mears H, Young G, Sanderson T, Harvey R, Barrett-Rodger J, Penn R, et al.
PLoS Biol
. 2025 Jan;
23(1):e3002982.
PMID: 39836705
Coronaviruses express their structural and accessory genes via a set of subgenomic RNAs, whose synthesis is directed by transcription regulatory sequences (TRSs) in the 5' genomic leader and upstream of...
9.
Black J, Bartha G, Abbott C, Boyle S, Karasaki T, Li B, et al.
Nat Med
. 2025 Jan;
31(1):70-76.
PMID: 39806071
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a...
10.
Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T, et al.
Nat Cancer
. 2025 Jan;
6(1):86-101.
PMID: 39789179
Human tumors are diverse in their natural history and response to treatment, which in part results from genetic and transcriptomic heterogeneity. In clinical practice, single-site needle biopsies are used to...